Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 18/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.47 |
| ▸ | UBE2M | P61081 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430387 | 0.89 | TRPV1 (0.60) | TRPV1OPRM1 | |
| SCHEMBL431333 | 0.86 | TRPV1 (0.49) | TRPV1OPRM1TEAD1UBE2MDCUN1D1 | |
| SCHEMBL431286 | 0.85 | TRPV1 (0.61) | TRPV1OPRM1 | |
| SCHEMBL429580 | 0.84 | TRPV1 (0.55) | TRPV1OPRM1TEAD1UBE2MDCUN1D1 | |
| SCHEMBL15021206 | 0.79 | TRPV1 (0.63) | TRPV1 | |
| SCHEMBL15021456 | 0.79 | TRPV1 (0.63) | TRPV1 | |
| SCHEMBL429994 | 0.78 | TRPV1 (0.59) | TRPV1OPRM1 | |
| SCHEMBL15021661 | 0.76 | TRPV1 (0.61) | TRPV1 | |
| SCHEMBL430783 | 0.75 | TRPV1 (0.57) | TRPV1 | |
| SCHEMBL430355 | 0.75 | TRPV1 (0.58) | TRPV1TEAD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBVIE, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8350083-B2 | Antagonists of the TRPV1 receptor and uses thereof | ABBVIE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2450346-A1 | Antagonists of the TRPV1 receptor and uses thereof | Abbott Laboratories (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| US-8030504-B2 | Pain, especially, inflammatory hyperalgesia, ostheoarthritic pain, chronic lower pain, allodynia, migraine. Methods of controlling pain and treating bladder overactivity and urinary incontinence | ABBOTT LABORATORIES (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885OPRM1 81/4885TEAD1 1626/4885 |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885OPRM1 80/4885TEAD1 1819/4885 |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885OPRM1 81/4885TEAD1 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.